CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
BERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business. Recent Corporate Highlights: On November 15, 2023, CorMedix received FDA approval for its new drug application (NDA) for DefenCath® (taurolidine and heparin). DefenCath is a catheter lock solution indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC).The Company received an outpatient reimbursement determination for DefenCath from the Center for Medicare & Medicaid Services (CMS), which confirmed that DefenCa
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCath [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCathGlobeNewswire
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)GlobeNewswire
- Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/12/24 - Miss
CRMD
Sec Filings
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- CRMD's page on the SEC website